Shots:
- Daiichi Sankyo has dosed the first patient with Enhertu ± radiotherapy in the P-III (DESTINY-Endometrial02) trial, conducted in collaboration with The GOG Foundation & ENGOT, with the GINECO as the lead ENGOT group
- The trial will evaluate the efficacy and safety of Enhertu (5.4mg/kg) ± radiotherapy vs SoC CT (carboplatin & paclitaxel) ± radiotherapy in ~710 treatment naïve pts with HER2 expressing (IHC 3+/2+) endometrial cancer
- Daiichi Sankyo discovered Enhertu, which is being jointly developed & commercialized by Daiichi Sankyo & AstraZeneca; based on various studies, Enhertu is approved in 85+ countries
Ref: Business Wire | Image: Daiichi Sankyo |Press Release
Related News: Daiichi Sankyo Reports the EMA’s MAA Validation of Datroway to Treat Metastatic Triple Negative Breast Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
